Antiviral activity of cidofovir against telomerase-specific replication-selective oncolytic adenovirus, OBP-301 (Telomelysin)

被引：6

作者：

Ouchi, Masaaki ^{[2
]}

Kawamura, Hitoshi ^{[2
]}

Urata, Yasuo ^{[2
]}

Fujiwara, Toshiyoshi ^{[1
]}

机构：

[1] Okayama Univ Hosp, Ctr Gene & Cell Therapy, Okayama 7008558, Japan

[2] Oncolys BioPharma Inc, Tokyo 1060032, Japan

来源：

INVESTIGATIONAL NEW DRUGS | 2009年 / 27卷 / 03期

关键词：

hTERT; Adenovirus; Cidofovir; Oncolytic virus; Clinical trial; CANCER; VIROTHERAPY; INFECTIONS; NUCLEOSIDE; VIRUS; DRUGS;

D O I：

10.1007/s10637-008-9169-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We constructed a replication-competent oncolytic adenovirus, OBP-301 (Telomelysin), in which human telomerase reverse transcriptase (hTERT) promoter drives E1 genes. OBP-301 is currently being used in a phase-I clinical trial for various types of tumors. Under such conditions, anti-adenoviral agents should be available for safety use against OBP-301 since any adenoviral viremia could cause severe adverse effects. Cidofovir (CDV) is an acyclic nucleoside phosphonate that has a broad antiviral activity against DNA viruses. Here, we examined the antiviral effects of CDV against OBP-301. The in vitro cytopathic effects of OBP-301 were suppressed by CDV. Moreover, CDV decreased the adenoviral E1A gene copy number after OBP-301 infection. These results suggest that CDV is a potentially useful antiviral agent for OBP-301.

引用

页码：241 / 245

页数：5

共 20 条

[1] Antiviral drugs for cytomegalovirus diseases [J].

Biron, Karen K. .

ANTIVIRAL RESEARCH, 2006, 71 (2-3) :154-163

[2] Use of replicating oncolytic adenoviruses in combination therapy for cancer [J].

Chu, RL ;

Post, DE ;

Khuri, FR ;

Van Meir, EG .

CLINICAL CANCER RESEARCH, 2004, 10 (16) :5299-5312

[3] Oncolytic virotherapy for cancer treatment: challenges and solutions [J].

Davis, JJ ;

Fang, B .

JOURNAL OF GENE MEDICINE, 2005, 7 (11) :1380-1389

[4] Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections [J].

De Clercq, E .

CLINICAL MICROBIOLOGY REVIEWS, 2003, 16 (04) :569-+

[5]

Gordon YJ, 1996, INVEST OPHTH VIS SCI, V37, P2774

[6] INHIBITORY EFFECT OF (S)-HPMPC, (S)-HPMPA, AND 2'-NOR-CYCLIC GMP ON CLINICAL OCULAR ADENOVIRAL ISOLATES IS SEROTYPE-DEPENDENT INVITRO [J].

GORDON, YJ ;

ROMANOWSKI, E ;

ARAULLOCRUZ, T ;

SEABERG, L ;

ERZURUM, S ;

TOLMAN, R ;

DECLERCQ, E .

ANTIVIRAL RESEARCH, 1991, 16 (01) :11-16

[7] Establishment of biological and pharmacokinetic assays of telomerase-specific replication-selective adenovirus [J].

Hashimoto, Yuuri ;

Watanabe, Yuichi ;

Shirakiya, Yoshiko ;

Uno, Futoshi ;

Kagawa, Shunsuke ;

Kawamura, Hitoshi ;

Nagai, Katsuyuki ;

Tanaka, Noriaki ;

Kumon, Horomi ;

Urata, Yasuo ;

Fujiwara, Toshiyoshi .

CANCER SCIENCE, 2008, 99 (02) :385-390

[8] Telomerase-specific replication-selective virotherapy for human cancer [J].

Kawashima, T ;

Kagawa, S ;

Kobayashi, N ;

Shirakiya, Y ;

Umeoka, T ;

Teraishi, F ;

Kyo, S ;

Taki, M ;

Tanaka, N ;

Fujiwara, T .

CLINICAL CANCER RESEARCH, 2004, 10 (01) :285-292

[9] SPECIFIC ASSOCIATION OF HUMAN TELOMERASE ACTIVITY WITH IMMORTAL CELLS AND CANCER [J].

KIM, NW ;

PIATYSZEK, MA ;

PROWSE, KR ;

HARLEY, CB ;

WEST, MD ;

HO, PLC ;

COVIELLO, GM ;

WRIGHT, WE ;

WEINRICH, SL ;

SHAY, JW .

SCIENCE, 1994, 266 (5193) :2011-2015

[10] Sequence changes in the human adenovirus type 5 DNA polymerase associated with resistance to the broad spectrum antiviral cidofovir [J].

Kinchington, PR ;

Araullo-Cruz, T ;

Vergnes, JP ;

Yates, K ;

Gordon, YJ .

ANTIVIRAL RESEARCH, 2002, 56 (01) :73-84

← 1 2 →